International Clinical Trial: A single-center, open-label, dose-escalation, single-dose phase I clinical trial to evaluate the pharmacokinetic/pharmacodynamic (PK/PD) characteristics of NovoPhase(R) in healthy Chinese male participants

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131571) titled 'A single-center, open-label, dose-escalation, single-dose phase I clinical trial to evaluate the pharmacokinetic/pharmacodynamic (PK/PD) characteristics of NovoPhase(R) in healthy Chinese male participants' on Sept. 4.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: West China Hospital of Sichuan University

Condition: None

Intervention: Group3:Dose: 3.50 U/kg (NovoRapid?/NovoLogix?) as a single subcutaneous abdominal injection. Group2:Dose: 2.80 U/kg (NovoRapid?/NovoLogix?) as a single subcutaneous abdominal injection.

Recruitment Status: Not Recruiting

Phase: 1

Date of Fir...